Phase III Data Support Premium Pricing For Vanda’s Sleep Drug Tasimelteon
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vanda anticipates that if approved, its drug for the rare “non-24-hour” circadian rhythm disorder will command pricing in line with orphan disease treatments. Second Phase III trial has it on track for a mid-2013 submission.
You may also be interested in...
Vanda’s Hetlioz Marketing: Disease Awareness DTC, Reps For Specialty Docs
Firm hopes strategy will educate patients about largely unknown condition, non-24 hour sleep-wake disorder, while using small sales force to target sleep experts.
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is developing treatments for schizophrenia by rescuing previously discontinued compounds and developing them into individualized therapeutics through the use of pharmacogenomics and pharmacogenetics.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.